Journal articleEur J Pharm Sci2018
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
- Journal
- Eur J Pharm Sci
- Published
- 31 January 2018
- Citations
- 16
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
The aim of this evaluation was to characterize the impact of the tumour size (TS) effects driven by the anticancer drug gemcitabine on overall survival (OS) in patients with advanced pancreatic cancer by building and validating a predictive semi-mechanistic joint TS-OS model. TS and OS data were obtained from one phase II and one phase III study where gemcitabine was administered (1000-1250 mg/kg over 30-60 min i.v infusion) as single agent to patients (n = 285) with advanced pancreatic cancer. … Excerpt only: this text is the publisher’s. Read it in full at the source.